4D MOLECULAR THERAPEUTICS INC. - COMMON STOCK

4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual Meeting

24 9 2021 07:03:00 提供 Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational Highlights

12 8 2021 16:04:00 提供 Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and License Agreement

24 6 2021 07:01:00 提供 Nasdaq GlobeNewswire

4D Molecular Therapeutics Appoints Carolyne Zimmermann as Chief Business Officer

07 6 2021 07:00:00 提供 Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

03 6 2021 07:00:01 提供 Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights

13 5 2021 16:03:00 提供 Nasdaq GlobeNewswire

4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME

12 5 2021 17:30:00 提供 Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution Platform

04 5 2021 16:02:00 提供 Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference

30 4 2021 07:05:00 提供 Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate Studies

27 4 2021 16:31:00 提供 Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights

25 3 2021 16:02:00 提供 Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry Disease

09 3 2021 08:03:00 提供 Nasdaq GlobeNewswire